Crossject Société Anonyme (ALCJ.PA)

Compare

1.4900

-0.2200

(-12.87%)

At close: 5:35:06 PM GMT+1

Key Events

Advanced Chart

Loading Chart for ALCJ.PA

Previous Close 1.7100
Open 1.6560
Bid --
Ask --
Day's Range 1.3440 - 1.6860
52 Week Range 1.3440 - 3.1800
Volume 785,784
Avg. Volume 90,473
Market Cap (intraday) 70.281M
Beta (5Y Monthly) 0.78
PE Ratio (TTM) --
EPS (TTM) -0.2500
Earnings Date Mar 27, 2025
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 4.30

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, a needle-free device for patient-side management disorders self-injectables. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. The company was founded in 2001 and is based in Dijon, France.

www.crossject.com

112

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Instruments & Supplies

Industry

CROSSJECT reports financial results for 2024

Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board

COMPLETION OF THE TRANSACTIONS ANNOUNCED IN DECEMBER 2024 RELATING TO THE AMENDMENT OF THE CONVERTIBLE BONDS SUBSCRIBED BY AN ENTITY AFFILIATED TO HEIGHTS CAPITAL MANAGEMENT, INC. (“HEIGHTS”) AND THE ISSUE OF A SECOND ASSIMILABLE TRANCHE

Crossject confirms ZEPIZURE® supply chain readiness with another successful ISO audit for Quality Management System

Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M

Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m

Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

Crossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions

Crossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization

Trailing total returns as of 3/27/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

ALCJ.PA

32.88%

CAC 40 (^FCHI)

8.26%

1-Year Return

ALCJ.PA

51.78%

CAC 40 (^FCHI)

2.62%

3-Year Return

ALCJ.PA

32.50%

CAC 40 (^FCHI)

21.92%

5-Year Return

ALCJ.PA

9.18%

CAC 40 (^FCHI)

83.62%

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

ALCJ.PA

Crossject Société Anonyme

1.4900

-12.87%

Mkt Cap EUR 70.281M